Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis

Annals of the Rheumatic Diseases

Volumn 72, Issue 10, 2013, Pages 1732-1736

  Chen, Xiao Xiang ^a,b   Baum, Wolfgang ^a   Dwyer, Denise ^c   Stock, Michael ^a   Schwabe, Kay ^a   Ke, Hua Zhu ^c   Stolina, Marina ^c   Schett, Georg ^a   Bozec, Aline ^a,d  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c AMGEN INC   (United States)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; SCLEROSTIN; SCLEROSTIN ANTIBODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; GLYCOPROTEIN; SOST PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; BONE NECROSIS; BONE REMODELING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; JOINT SWELLING; MONOTHERAPY; MOUSE; NONHUMAN; OSTEOLYSIS; PERIARTICULAR JOINT DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPINE; SYNOVITIS; SYSTEMIC DISEASE; TIBIA; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTICULAR CARTILAGE; BONE DISEASES, METABOLIC; BONE REGENERATION; CARTILAGE DISEASES; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL ARTHRITIS; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; BONE DISEASES, METABOLIC; BONE REGENERATION; CARTILAGE DISEASES; CARTILAGE, ARTICULAR; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; FEMALE; GLYCOPROTEINS; MICE; MICE, TRANSGENIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883818516     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203345     Document Type: Article

References (18)

1. McInnes IB, Schett G. The pathogenesisi of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
2. Dequeker J, Geusens P. Osteoporosis and arthritis. Ann Rheum Dis 1990;49:276-80. (Pubitemid 20168781)
3. Schett G, Saag KG, Bijlsma JW. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 2010;69:1415-19.
4. van den Broek M, Dirven L, de Vries-Bouwstra JK, et al. Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up. Ann Rheum Dis 2012;71:1530-3.
5. Finzel S, Rech J, Schmidt S, et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis 2011;70:1587-93.
6. Eekman DA, Vis M, Bultink IE, et al. Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:389-90.
7. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537-43. (Pubitemid 32184286)
8. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68:577-89. (Pubitemid 32202753)
9. Papapoulos SE. Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis 2011;70:i119-22.
10. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24:578-88.
11. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011;26:1012-21.
12. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
13. de Rooy DP, Yeremenko NG, Wilson AG, et al. Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2013;72:769-75.
14. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
15. Schett G, Redlich K, Hayer S, et al, Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003;48:2042-51. (Pubitemid 36828700)
16. Freeston JE, Garnero P, Wakefield RJ, et al. Urinary type II collagen C-terminal peptide is associated with synovitis and predicts structural bone loss in very early inflammatory arthritis. Ann Rheum Dis 2011;70:331-3.
17. Pye SR, Adams JE, Ward KA, et al. Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss. Rheumatology 2010;49:1943-8.
18. Roudier M, Li X, Niu QT, et al. Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury. Arthritis Rheum 2013;65:721-31.